Fosun Pharma Unit's Levalbuterol Solution Wins NMPA Approval for Bronchospasm
Fosun Pharma announced that the drug registration application for Levalbuterol Hydrochloride Nebulized Inhalation Solution, submitted by its controlled subsidiary Fosun Pharma (Xuzhou) Co. , Ltd. , has been approved by the National Medical Products Administration. The approved indication covers the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children aged 6 years and above.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.